EPISODE · Jul 25, 2022 · 27 MIN
What are the pros and cons of bispecific antibodies for multiple myeloma?
from Multiple Myeloma Hub
During the ASCO 2022 Congress, the Multiple Myeloma Hub was pleased to speak to Roberto Mina, University of Turin, Turin, IT, and Andrzej J. Jakubowiak, The University of Chicago, Chicago, US. We asked, What are the pros and cons of bispecific antibodies for multiple myeloma? Mina and Jakubowiak discuss the MajesTEC-1 and MagnetisMM-1 trials, the efficacy and response rates of bispecific antibodies, and the challenges of using bispecific antibodies, such as infection risk. They also compare bispecific antibodies to CAR T-cell therapies and talk about the sequencing of therapies in myeloma treatment. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
During the ASCO 2022 Congress, the Multiple Myeloma Hub was pleased to speak to Roberto Mina, University of Turin, Turin, IT, and Andrzej J. Jakubowiak, The University of Chicago, Chicago, US. We asked, What are the pros and cons of bispecific antibodies for multiple myeloma? Mina and Jakubowiak discuss the MajesTEC-1 and MagnetisMM-1 trials, the efficacy and response rates of bispecific antibodies, and the challenges of using bispecific antibodies, such as infection risk. They also compare bispecific antibodies to CAR T-cell therapies and talk about the sequencing of therapies in myeloma treatment. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
What are the pros and cons of bispecific antibodies for multiple myeloma?
No transcript for this episode yet
Similar Episodes
Apr 6, 2026 ·25m
Mar 30, 2026 ·27m